NASDAQ
12.65USD
+0.34 (+2.76%)
We have scored 9 news catalysts on AbCellera Biologics Inc. (ABCL) over the past 12 months. The biggest single-day move next to one of them came Aug 10, 2026, when ABCL closed +34.8%: “This Biotech's Drug Could Treat Hot Flashes. The Stock Is Up 32% on Good News.”. Coverage across the window leans positive (average ticker sentiment +0.43). Most of the impact sits in sector healthcare and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3.9B
P/E
—
EPS
—
Beta
1.19
52W range
2.745-13.18
Day range
11.78–12.68
Open
12.11
Prev close
12.31
Volume
5M
Avg volume
7.3M
Dividend
0.00
IPO
2020-12-11
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about AbCellera Biologics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ABCL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
